



Cohere Medical Policy – Positron Emission Tomography (PET), Cardiac

Clinical Guidelines for Medical Necessity Review

Version: 2
Effective Date: October 30, 2024

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2024 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Positron Emission Tomography (PET), Cardiac

Date of last literature review: 7/29/2024

Document last updated: 10/30/2024

Type: ☒ Adult (18+ yo) | ☒ Pediatric (0-17 yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Positron Emission Tomography (PET), Cardiac	4
Recommended Clinical Approach	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	7
Disclaimer on Radiation Exposure in Pediatric Population	7
Procedure Codes (CPT/HCPCS)	8
Medical Evidence	10
References	12
Clinical Guideline Revision History/Information	15

Medical Necessity Criteria

Service: Positron Emission Tomography (PET), Cardiac

Recommended Clinical Approach

Cardiac PET is considered advanced imaging, and it is best utilized per institutional internal medicine and cardiology protocols. Radiologic and cardiology guidelines from the American Society of Nuclear Cardiology (ASNC), American College of Radiology (ACR), American College of Cardiology (ACC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and European Association of Nuclear Medicine (EANM) may be consulted prior to ordering.

Cardiac PET is specifically optimized for the evaluation of myocardial perfusion and viability. It may also be utilized to evaluate infection and inflammation. Myocardial perfusion in the setting of suspected or known coronary artery disease (CAD) can be evaluated with cyclotron-produced (^{13}N -ammonia) or generator-produced (^{82}Rb) PET agents.¹⁻¹⁶

Medical Necessity Criteria

Indications

→ **Positron emission tomography (PET), cardiac** is considered appropriate if **ANY** of the following is **TRUE**:

◆ **Cardiac PET or PET/CT** for **ANY** of the following²:

- The patient is asymptomatic with known CAD or a high pretest probability (PTP) of CAD (See the [Pre-Test Probability of CAD](#) published by the CAD Consortium) with **ANY** of the following:
 - Equivocal prior coronary CT angiography (CCTA, with 40–90% stenosis); **OR**
 - Equivocal exercise stress test; **OR**
 - History of coronary artery bypass grafting and no stress test performed in the last 5 years prior; **OR**
 - History of percutaneous coronary intervention and no stress test performed in the last 2 years prior; **OR**
 - Coronary artery calcium score equal to or above 400; **OR**

- New left ventricular dysfunction (ejection fraction [EF] less than or equal to 45%); **OR**
- The patient is symptomatic with suspected or known coronary artery disease (CAD) and imaging is recommended for **ANY** of the following reasons:
 - Detection of obstructive CAD with myocardial ischemia in patients with chest pain (acute but stabilized or chronic); **OR**
 - Intermediate or high pretest probability; **OR**
 - For clarification of equivocal or discordant prior tests and **ANY** of the following is **TRUE**:
 - ◆ Presence of anomalous coronary arteries with suspected ischemia; **OR**
 - ◆ Presence of borderline obstructive lesions on coronary angiography (50–70% non-left main stenosis or CCTA (40–90% stenosis); **OR**
 - New heart failure diagnosis without previous assessment for CAD with **ANY** of the following:
 - ◆ Heart failure with preserved ejection fraction (intermediate or high-risk of CAD); **OR**
 - ◆ Ejection fraction less than 45% (any clinical risk of CAD)³; **OR**
 - Pre-operative risk assessment before high-risk surgical procedures (e.g., vascular surgery, kidney/liver/lung transplantation); **OR**
 - Post-operative assessment of reimplanted coronary arteries (e.g., surgically corrected transposition of the great arteries); **OR**
- Evaluation or surveillance for **ANY** of the following:
 - For assessment of myocardial blood flow in suspected microvascular disease; **OR**
 - Myocardial viability for detection of hibernating or stunned myocardium; **OR**
- ◆ **FDG PET/CT** and **ANY** of the following is **TRUE**¹³:
 - Evaluation for **ANY** of the following:
 - An abnormality considered indeterminate by another imaging modality to determine whether glucose metabolism in that abnormality favors a benign or malignant process; **OR**

- Cardiomyopathy (inflammatory or restrictive) and ischemic cardiomyopathy has been excluded¹⁴; **OR**
- Ventricular arrhythmia (frequent PVCs, non-sustained ventricular tachycardia, sustained ventricular tachycardia, or cardiac arrest)^{15,16}; **OR**
- Infective endocarditis (known or suspected)^{17,18}; **OR**
- Myocardial viability assessment and **ALL** of the following is **TRUE**:
 - ◆ Determination of the appropriateness of invasive revascularization management; **AND**
 - ◆ Ischemic heart failure; **OR**
- Nontraumatic chest wall pain with a normal chest radiography and **ANY** of the following¹⁹:
 - ◆ History of prior chest intervention; **OR**
 - ◆ Known or suspected malignancy; **OR**
 - ◆ Suspected infectious or inflammatory condition; **OR**
- Cardiac sarcoidosis⁴⁻⁵; **OR**
- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:
 - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**
 - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

- **Positron Emission Tomography (PET), cardiac** is not considered appropriate if **ANY** of the following is **TRUE**:
- ◆ The patient has undergone advanced imaging of the same body part and for the same indication within 3 months without undergoing treatment or developing new or worsening symptoms⁶; **OR**
 - ◆ The imaging request is for **myocardial perfusion PET** and **ANY** of the following is **TRUE**:

- Acute nonspecific chest pain with a low probability of CAD⁷; **OR**
 - Asymptomatic patients with less than an intermediate risk for CAD who may benefit from CT coronary calcium or coronary CT angiography; **OR**
 - Chest trauma^{5,20}; **OR**
 - Nonischemic myocardial disease (excluding sarcoidosis)⁴⁻⁵; **OR**
- ◆ The imaging request is for **FDG PET/CT**, and **ANY** of the following is **TRUE**:
- Acute chest pain with suspected aortic dissection; **OR**
 - Chest trauma²⁰; **OR**
 - Congenital or acquired heart disease²¹; **OR**
 - Nonischemic myocardial disease (excluding sarcoidosis)⁴⁻⁵

*NOTE: PET in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

**NOTE: PET scans should be scheduled at least 4–6 weeks after radiation therapy or surgery to avoid false positives due to inflammation from recent treatments.

Disclaimer on Radiation Exposure in Pediatric Population

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.²³⁻²⁴

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT,

fluoroscopy, or radiography.²²⁻²³

Cumulative Dose Monitoring: Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.²²⁻²³

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.²²⁻²³

Cohere Imaging Gently Guideline

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

Level of Care Criteria
Inpatient or Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
78429	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan
78430	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography
78431	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography (CT) transmission

	scan
78432	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability)
78433	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography (CT) transmission scan
78459	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study
78491	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic)
78492	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic)
78811	Positron emission tomography (PET) imaging; limited area (e.g., of chest, head/neck)

Medical Evidence

Patel et al. (2020) assess the use of positron emission tomography (PET) myocardial perfusion imaging (MPI) as a way to non-invasively measure myocardial blood flow reserve (MBFR). One aim was to determine if patients with MBFR with a survival benefit after revascularization, which helps guide post-test management. A total of 12594 patients who underwent Rb82 rest/stress PET MPI were included. The MBFR observed on PET MPI correlates with overall mortality risk and can pinpoint individuals who would potentially derive survival advantages from early revascularization as opposed to medical management alone. The authors conclude that utilization of the metric can inform decision-making regarding revascularization strategies, however, further validation through prospective studies is warranted.²⁴

Gulati et al. (2021) recommended for intermediate-high risk patients with stable chest pain and no known CAD for whom rest/stress nuclear MPI is selected, PET is reasonable in preference to SPECT, if available to improve diagnostic accuracy and decrease the rate of nondiagnostic test results.²⁵

Swart et al. (2018) performed a multicenter study to enhance the accuracy of ¹⁸F-Fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) in patients suspected of having prosthetic heart valve endocarditis (PVE). The study identified and eliminated potential confounding factors using visual and standardized quantitative evaluations. A total of 160 patients with a prosthetic heart valve were included (median age 62; 68% male; 82 mechanical valves; 62 biological; 9 transcatheter aortic valve replacements; 7 other). All patients underwent FDG PET/CT for suspicion of PVE. Early integration of FDG PET/CT into the diagnostic protocol is shown to mitigate the potential impact of low inflammatory activity (for example, that induced by prolonged antibiotic treatment).¹⁸

Chen et al. (2017) conducted the CORE320 Multicenter Study (NCT00934037) to compare the prognostic significance of combined CT angiography and CT myocardial stress perfusion imaging vs a combination of invasive coronary angiography (ICA) and stress single photon emission CT myocardial perfusion imaging. The study also addressed the time to major adverse cardiovascular events (MACE). Results indicate that the combined use of CT angiography and CT myocardial perfusion demonstrates comparable predictive ability for 2-year MACE-free survival. This encompasses the necessity for myocardial revascularization procedures compared to the standard approach involving ICA and single photon emission CT perfusion imaging.⁹

References

1. Peix A, Mesquita CT, Paez D, et al. Nuclear medicine in the management of patients with heart failure: Guidance from an expert panel of the International Atomic Energy Agency (IAEA). *Nucl Med Commun*. 2014 Aug;35(8):818–23. doi: 10.1097/MNM.0000000000000143. PMID: 24781009; PMCID: PMC4076031.
2. American College of Radiology (ACR), American College of Nuclear Medicine (ACNM), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Pediatric Radiology (SPR), Society of Thoracic Radiology (STR). ACR–ACNM–SNMMI–SPR–STR practice parameter for the performance of cardiac positron emission tomography computed tomography (PET/CT) – resolution 23. Updated 2023. Accessed February 27, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CardiacPET-CT.pdf>.
3. White RD, Kirsch J, et al. ACR appropriateness criteria – suspected new onset and known non acute heart failure. *J Am Coll Radiol*. 2018 Nov;15(11S):S418–S431. doi: 10.1016/j.jacr.2018.09.031. PMID: 30392610.
4. Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. *Heart Rhythm*. 2015 Dec;12(12):2488–98. doi: 10.1016/j.hrthm.2015.08.014. PMID: 26272522; PMCID: PMC4656080.
5. Beton O, Kurmus O, Asarcikli LD, et al. The practical value of technetium-99m-MIBI SPET to differentiate between ischemic and non-ischemic heart failure presenting with exertional dyspnea. *Hell J Nucl Med*. 2016 May–Aug;19(2):147–54. doi: 10.1967/s002449910369. PMID: 27331209.
6. Wasser EJ, Prevedello LM, Sodickson A, Mar W, Khorasani R. Impact of a real-time computerized duplicate alert system on the utilization of computed tomography. *JAMA Intern Med*. 2013;173(11):1024–1026. doi: 10.1001/jamainternmed.2013.543. PMID: 23609029.
7. American College of Radiology (ACR), North American Society for Cardiovascular Imaging (NASCI), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Pediatric Radiology (SPR), Society of Thoracic Radiology (STR). ACR–NASCI–SNMMI–SPR–STR practice parameter for the performance of cardiac scintigraphy – resolution 36. Updated 2019. Accessed February 27, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CardiacScint.pdf>.
8. Romero J, Husain SA, Holmes AA, et al. Non-invasive assessment of low-risk acute chest pain in the emergency department: A comparative

- meta-analysis of prospective studies. *Int J Cardiol*. 2015;187:565–80. doi: 10.1016/j.ijcard.2015.01.032. PMID: 25863305.
9. Chen MY, Rochitte CE, Arbab-Zadeh A, et al. Prognostic value of combined CT angiography and myocardial perfusion imaging versus invasive coronary angiography and nuclear stress perfusion imaging in the prediction of major adverse cardiovascular events: The CORE320 Multicenter Study. *Radiology*. 2017;284(1):55–65. doi: 10.1148/radiol.2017161565. PMID: 28290782; PMCID: PMC5495129.
 10. Batlle JC, Kirsch J, et al. ACR appropriateness criteria – chest pain, possible acute coronary syndrome. *J Am Coll Radiol*. 2020 May;17(5S):S55–S69. doi: 10.1016/j.jacr.2020.01.027. PMID: 32370978.
 11. Litmanovich D, Hurwitz LM, et al. ACR appropriateness criteria – chronic chest pain–high probability of coronary artery disease: 2021 update. *J Am Coll Radiol*. 2022 May;19(5S):S1–S18. doi: 10.1016/j.jacr.2022.02.021. PMID: 35550795.
 12. Shah AB, Kirsch J, et al. ACR appropriateness criteria – chronic chest pain, noncardiac etiology unlikely (low to intermediate probability of coronary artery disease). *J Am Coll Radiol*. 2018 Nov;15(11S):S283–S290. doi: 10.1016/j.jacr.2018.09.021. PMID: 30392597.
 13. American College of Radiology (ACR), American College of Nuclear Medicine (ACNM), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Pediatric Radiology (SPR). ACR–ACNM–SNMMI–SPR practice parameter for performing FDG–PET/CT in oncology – resolution 21. Updated 2020. Accessed February 26, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/fdg-pet-ct.pdf>.
 14. Rajiah P, Kirsch J, et al. ACR appropriateness criteria – nonischemic myocardial disease with clinical manifestations (ischemic cardiomyopathy already excluded). *J Am Coll Radiol*. 2021 May;18(5S):S83–S105. doi: 10.1016/j.jacr.2021.01.019. PMID: 33651982.
 15. Bolen MA, Saeedan MNB, et al. ACR appropriateness criteria – dyspnea–suspected cardiac origin (ischemia already excluded): 2021 update. *J Am Coll Radiol*. 2022 May;19(5S):S37–S52. doi: 10.1016/j.jacr.2022.02.014. PMID: 35550804.
 16. Winchester DE, Maron DJ, Blankstein R, et al. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multimodality appropriate use criteria for the detection and risk assessment of chronic coronary disease: a report of the American College of Cardiology Solution Set Oversight Committee, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, American Society of Preventive Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance Imaging, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2023;81(25):2445–2467.

17. Malik SB, Hsu JY, et al. ACR appropriateness criteria – infective endocarditis. *J Am Coll Radiol*. 2021 May;18(5S):S52–S61. doi: 10.1016/j.jacr.2021.01.010. PMID: 33958118.
18. Swart LS, Gomes A, Scholtens AM, et al. Improving the diagnostic performance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis. *Circulation*. 2018 Oct 2;138(14):1412–1427. doi: 10.1161/CIRCULATIONAHA.118.035032. PMID: 30018167.
19. Stowell JT, Walker CM, et al. ACR appropriateness criteria – nontraumatic chest wall pain. *J Am Coll Radiol*. 2021 Nov;18(11S):S394–S405. doi: 10.1016/j.jacr.2021.08.004. PMID: 34794596.
20. Stojanovska J, Hurwitz LM, et al. ACR appropriateness criteria – blunt chest trauma, suspected cardiac injury. *J Am Coll Radiol*. 2020 Nov;17(11S):S380–S390. doi: 10.1016/j.jacr.2020.09.012. PMID: 33153551.
21. Krishnamurthy R, Suman G, et al. ACR appropriateness criteria – congenital or acquired heart disease. *J Am Coll Radiol*. 2023 Nov;20(11S):S351–S381. doi: 10.1016/j.jacr.2023.08.018. PMID: 38040460.
22. The Image Gently Alliance. Procedures – cardiac imaging. Updated 2014. Accessed June 26, 2024. <https://www.imagegently.org/Procedures/Cardiac-Imaging>.
23. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed June 26, 2024. <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.
24. Patel KK, Spertus JA, Chan PS, et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. *Eur Heart J*. 2020 Feb 1;41(6):759–768. doi: 10.1093/eurheartj/ehz389. PMID: 31228200; PMCID: PMC7828468.
25. Gulati M, Levy PD, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 78(22):e187–e285.

Clinical Guideline Revision History/Information

Original Date: August 5, 2024		
Review History		
Version 2	10/30/2024	Edited repeat imaging criteria language.